MedTechs Adjust 2025 Outlook Amid Tariffs: What Investors Need to KnowZacks Investment Research • 05/05/25
2 Stocks, 2 Decades, $200. Is This the Long-Term Dividend Play for Your Portfolio?The Motley Fool • 05/03/25
US judge allows testimony that Abbott and Mead Johnson preterm baby formula caused deadly diseaseReuters • 05/02/25
MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at RacesPRNewsWire • 05/01/25
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loomCNBC • 04/30/25
Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring InformationPRNewsWire • 04/29/25
Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing TechnologyPRNewsWire • 04/27/25
New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFibPRNewsWire • 04/26/25
Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock?Zacks Investment Research • 04/25/25
EPD Growth in Emerging Market Supports Abbott Stock Amid Macro WoesZacks Investment Research • 04/24/25
These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected EarningsBenzinga • 04/17/25
Compared to Estimates, Abbott (ABT) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 04/16/25
Abbott Laboratories Dips As Sales Come In Light Despite Profit BeatInvestors Business Daily • 04/16/25